Fusion Antibodies (LSE:FAB) Gross Profit : £0.36 Mil (TTM As of Sep. 2024)

Fusion Antibodies Gross Profit Chart

Fusion Antibodies Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
Gross Profit		Get a 7-Day Free Trial					1.77	2.02	2.47	0.57	-0.05

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Gross Profit	Get a 7-Day Free Trial													0.61	-0.03	-0.08	0.04	0.33

Competitive Comparison of Fusion Antibodies's Gross Profit

For the Biotechnology subindustry, Fusion Antibodies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Gross Profit distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Gross Profit falls into.

Fusion Antibodies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Fusion Antibodies's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Fusion Antibodies's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.36 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Fusion Antibodies's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Fusion Antibodies  (LSE:FAB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Fusion Antibodies had a gross margin of 26.93% for the quarter that ended in Sep. 2024 => Competition eroding margins

Fusion Antibodies Gross Profit Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies Business Description